- Stocks
- Pharma & Healthcare
- Innova Captab
Innova Captab share price
NSE: INNOVACAPPharma & HealthcareDrug Manufacturers - Specialty & Generic
Innova Captab at a glance
Innova Captab (NSE: INNOVACAP) closed at ₹983.60 on 22 Oct 2026, up 0.57% on the day. With a market capitalisation of ₹5,629 Cr, it ranks 743rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 40× trailing earnings, against a return on equity of 12.9% in FY26. Over the past year the share price has risen 17.9%. Its 52-week range is ₹622.00 (2 Mar 2026) to ₹1,353.50 (23 Sep 2026); the last close is 27.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹448 Cr (+42.3% year on year) and net profit ₹38 Cr (+28.8%), on a consolidated basis. Promoters held 50.90% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹5,629 CrRank 743 on NSE
- P/E (trailing)
- 40×
- Price to book
- 3.61×FY26
- EPS (TTM)
- ₹24.62to Q4 FY26
- ROE
- 12.9%FY26
- ROCE
- 15.3%FY26
- Debt to equity
- 0.31FY26
- Net profit margin
- 8.6%FY26
- Book value / share
- ₹190.61FY26
- Dividend payout
- 8.1%FY26
- 52-week high
- ₹1,353.5023 Sep 2026
- 52-week low
- ₹622.002 Mar 2026
- 1-year return
- +17.9%
- RSI (14-day)
- 29.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.57% | −6.7% | −17.8% | +1.0% | +17.9% |
Innova Captab quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹294 Cr | ₹318 Cr | ₹316 Cr | ₹315 Cr | ₹352 Cr | ₹380 Cr | ₹450 Cr | ₹448 Cr |
| Revenue YoY | +26.2% | +12.5% | +4.6% | +19.8% | +19.5% | +19.5% | +42.3% | +42.3% |
| Net profit | ₹29 Cr | ₹35 Cr | ₹34 Cr | ₹30 Cr | ₹31 Cr | ₹30 Cr | ₹42 Cr | ₹38 Cr |
| Net profit YoY | +67.6% | +52.8% | +36.1% | +3.0% | +5.2% | −15.2% | +23.2% | +28.8% |
| Net margin | 10.0% | 11.0% | 10.8% | 9.4% | 8.8% | 7.8% | 9.4% | 8.5% |
| EPS | ₹5.15 | ₹6.12 | ₹5.97 | ₹5.17 | ₹5.42 | ₹5.18 | ₹7.37 | ₹6.65 |
Innova Captab financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹411 Cr | ₹801 Cr | ₹926 Cr | ₹1,081 Cr | ₹1,244 Cr | — |
| Operating profit | ₹46 Cr | ₹86 Cr | ₹92 Cr | ₹130 Cr | ₹171 Cr | — |
| Net profit | ₹35 Cr | ₹64 Cr | ₹68 Cr | ₹94 Cr | ₹128 Cr | — |
| EPS (₹) | ₹7.00 | ₹13.00 | ₹14.00 | ₹19.00 | ₹22.00 | — |
| Cash from operations | ₹42 Cr | ₹59 Cr | ₹67 Cr | ₹146 Cr | ₹64 Cr | — |
| Total debt | ₹6 Cr | ₹67 Cr | ₹87 Cr | ₹208 Cr | ₹244 Cr | ₹215 Cr |
| Shareholders' equity | ₹145 Cr | ₹209 Cr | ₹323 Cr | ₹831 Cr | ₹959 Cr | ₹1,091 Cr |
Innova Captab shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.90% | 50.90% | 50.90% | 50.90% | 50.90% | 50.90% |
| Foreign institutions | 0.34% | 0.23% | 0.08% | 0.11% | 0.23% | 0.34% |
| Domestic institutions | 19.76% | 19.67% | 20.17% | 20.24% | 20.14% | 19.92% |
| Non-institutions | 28.99% | 29.20% | 28.85% | 28.76% | 28.73% | 28.84% |
Innova Captab vs peers
The listed Pharma & Healthcare companies nearest to Innova Captab by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KOVAIKovai Medical Center & Hospital | ₹5,738.00 | −2.24% | +190.4% | ₹6,279 Cr | 25.7 | — |
| NEPHROPLUSNephrocare Health Services | ₹599.90 | −0.84% | — | ₹6,019 Cr | 74.1 | — |
| SPARCSun Pharma Advanced Research Company | ₹176.82 | −1.22% | +35.4% | ₹5,738 Cr | 3.7 | — |
| SENORESSenores Pharmaceuticals | ₹1,233.30 | +0.35% | +71.0% | ₹5,680 Cr | 46.7 | — |
| INNOVACAPInnova Captab | ₹983.60 | +0.57% | +17.9% | ₹5,629 Cr | 40 | — |
| FDCFDC | ₹339.20 | −0.24% | −22.1% | ₹5,523 Cr | — | — |
| IOLCPIOL Chemicals and Pharmaceuticals | ₹173.27 | −0.76% | +80.5% | ₹5,086 Cr | 36.9 | — |
Ask anything about Innova Captab
Pivot answers on the live chart with evidence you can check, and tests strategies against INNOVACAP's own history. Try: “Why has INNOVACAP moved over the last three months?” · “Backtest a 50-day moving-average crossover on INNOVACAP over five years” · “Compare INNOVACAP with KOVAI on margins and valuation”
Frequently asked questions about Innova Captab
What is the share price of Innova Captab today?
Innova Captab (NSE: INNOVACAP) last closed at ₹983.60 on 22 Oct 2026. Its 52-week high is ₹1,353.50 and its 52-week low is ₹622.00.
What is the market cap of Innova Captab?
Innova Captab's market capitalisation is ₹5,629 Cr (₹5,629 Cr) at the 22 Oct 2026 close, ranking 743rd among the NSE companies Pivot tracks.
What is the P/E ratio of Innova Captab?
Innova Captab trades at a trailing P/E of 40. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 36.9.
What is the ROE and ROCE of Innova Captab?
Return on equity was 12.9% in FY26 and return on capital employed was 15.3% in FY26 (consolidated figures).
Is Innova Captab a debt-free company?
No. Innova Captab's debt-to-equity ratio was 0.31 in FY26, with total debt of ₹215 Cr.
What were Innova Captab's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Innova Captab reported revenue of ₹448 Cr, +42.3% year on year, and net profit of ₹38 Cr, +28.8% year on year.
How has Innova Captab stock performed over the last year?
Innova Captab's share price has risen 17.9% over the past year, +1.0% over three months and −17.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Innova Captab?
As of 30 Jun 2026: promoters 50.90%, foreign institutions 0.34%, domestic institutions 19.92%, non-institutions 28.84%.
Who are Innova Captab's competitors?
The listed Pharma & Healthcare companies closest to Innova Captab by market cap are Kovai Medical Center & Hospital, Nephrocare Health Services, Sun Pharma Advanced Research Company, Senores Pharmaceuticals, FDC and IOL Chemicals and Pharmaceuticals.
Is Innova Captab a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Innova Captab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on INNOVACAP against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with I · all NSE stocks · this page as text